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UMBILICAL CORD BLOOD TRANSPLANTATION FOR TRANSFUSION-
DEPENDENT THALASSEMIA AND SICKLE CELL DISEASE
Walters, Mark. Children’s Hospital Oakland Research Institute, Oak-
land, CA.
Sickle cell anemia and -thalassemia major are clinically signiﬁ-
cant hereditary anemias that elicit world-wide attention due to the
frequency and severity of these disorders. Historically, most chil-
dren who inherited these disorders died in the ﬁrst decade of life.
In the contemporary era, however, supportive care has extended
lifespan through the 5th decade of life and beyond, with survival
through early adulthood now indistinguishable from those unaf-
fected by these disorders. As a result, chronic health impairments
that signiﬁcantly reduce the quality of life have become the prin-
cipal challenge in -thalassemia major and sickle cell anemia.
Thus, the application of hematopoietic cell transplantation and its
inherent risk of mortality in the short-term must be balanced by
the beneﬁt of survival without the burden of chronic illness in the
long-term. Toward this end, the development of umbilical cord
blood transplantation (UCBT) represents a signiﬁcant advance due
to its association with a lower risk of graft-versus-host disease
(GVHD), the leading cause of mortality and morbidity after HCT
for hemoglobinopathies. We have observed outcomes after UCBT
that are identical to earlier results of bone marrow transplantation
for hemoglobinopathies. In our multi-center series of patients
treated by HLA-identical sibling UCBT, 26 of 29 (90%) survive,
and 25 (86%) survive disease-free. Overall, the Kaplan-Meier
probabilities of survival and event-free survival after sibling UCBT
are 89% and 86%, respectively with a median follow-up of 1.3
(range, 0.1-7.6) years. The cumulative incidence of graft failure was
4%. Results after unrelated donor UCBT remain limited, but
suggest encouraging results, particularly with regard to the rates of
acute and chronic GVHD. UCBT in lieu of more conventional
sources of hematopoietic cells may be particularly advantageous when
there is urgency for transplantation and in non-malignant disorders
where GVHD, in particular, has a negative impact upon outcome.
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UNRELATED CORD BLOOD TRANSPLANTATION (CBT) FOR HEMOGLO-
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Jaing, Tang-Her,1 Tan, Patrick,2 Rosenthal, Joseph,3 Wang, Brian,4
Gjertson, David,4,5 Petz, Lawrence D.,5,6 Chow, Robert.6,7,8 1Chang
Gung University & Children’s Hospital, Linko, Taiwan; 2Haematology
& Stem Cell Transplant Center, Mount Elizabeth Hospital, Singapore;
3City of Hope National Medical Center, Duarte, CA; 4UCLA School of
Public Health and 5UCLA Medical Center, Los Angeles, CA; 6StemCyte
International Cord Blood Center, Arcadia, CA; 7StemCyte Taiwan
National Cord Blood Center, Linko, Taiwan; 8StemCyte Research In-
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Unrelated umbilical cord blood transplantation (CBT) is a po-
tentially curative therapy for most hemoglobinopathy patients;
however, cell dosage is a critical factor for CBT. We previously
showed that by combining strategies that maximize cell dose, that
is, non-red cell reduced plasma depleted cord blood (PD CB),
forego post-thaw wash, and double cord blood transplantation
when needed—promising results may be achieved with unrelated
CBT in selected patients (Jaing et al, BBMT 2005;11:349). Be-
tween July 1991 and April 2006, 45 unrelated CBT were per-
formed after myeloablative therapy in 38 pediatric patients with
transfusion-dependent hemoglobinopathy (36 thalassemia and 2
SCD) at the authors’ institutions and 11 other centers using mostly
PDCB units that were not washed after thawing (6 double cords
and 1 re-transplant). Nineteen patients were Pesaro class 1, four
class 2, and one class 3, with 14 status unknown. The median age
of patients was 6 years old (range 0.3-20 yr) with a median weight
of 19 kg (range 8-76 kg). All PD CB data were audited internally
and externally and the primary data for the 15 patients at Chang
Gung were audited by one of the authors (JR).
No signiﬁcant adverse events were observed after direct infusion
despite major ABO incompatibility in 9 cases.
Unadjusted ANC 500 and platelet 20,000 engraftment cumulative
incidence with donor chimerism was achieved in 81  7% and 79 
8% of the cases, and median times to ANC500 engraftment, and
platelet 20,000 engraftment were 17 (range 11-33 days) and 37 (range
16-133 days) days after transplantation, respectively (Table 4).
Eight patients died with 3 deaths unrelated to the CBU (2 early
deaths prior to day 20 and one accident). All remaining 30 patients
Table 4. Summary of Clinical Outcome Based on Experience and Washing
Autologous
Recovery 1 Yr. OS
1 Yr.
DFS
Unadjusted Cumulative Incidence
III-IV aGVHD
Extensive
cGVHDANC500 Plt20K Plt50K
Less experienced 15% 63% 45% 71% 56% 56% 0% 0%
Experienced 11% 87% 77% 87% 86% 86% 16% 10%
Not Washed 12% 83% 72% 83% 86% 82% 13% 8%
Washed 17% 55% 26% 70% 40% 40% 0% 0%
Overall 13  6% 77  7% 65  8% 81  7% 79  8% 76  8% 11% 6%
Table 5. Summary of Graft Parameters Based on Experience and Washing
Patients,
n
CBU,
n
HLA
Matches, n
Prefreeze
TNC Dose
Post-thaw
TNC Dose
TNC
Recovery
Prefreeze
CD34 Dose
Post-thaw
CD34 Dose
CD34 Cell
Recovery
Less experienced 15 15 5.0 6.8 2.6 83% 3.6 1.1 39%
Experienced 23 30 4.0 8.9 6.6 89% 3.4 3.3 99%
Not washed 31 38 4.0 9.1 5.6 81% 3.5 2.9 83%
Washed 7 7 5.0 6.4 2.1 NA 3.9 3.1 NA
Overall 38 45 4.0 8.1 5.6 82% 3.4 2.9 84%
Table 3. Interaction between HLA Mismatches, Number of Cells and
Outcomes in Unrelated Cord Blood Transplants for Non-Malignant
Diseases
Number of
HLA MM 0-1
vs 2 vs 3-4
Type of
HLA MM
Class I vs II
Interaction with
Number of Cells
PMN engraftment Less More 2 DRB1  Less <cells and >MM
Platelet engraftment Less More 2 DRB1  Less <cells and >MM
TRM More Less 2 DRB1  Less <cells and >MM
AGVHD More Same More >cells and >MM
CGVHD More Same More >cells and >MM
LFS, OS Less Better 2 DRB1  Worse if HLA MM >2 and
NC <3.5 NC/kg
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